# ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

> **NCT06418711** · PHASE3 · TERMINATED · sponsor: **Mannkind Corporation** · enrollment: 132 (actual)

## Conditions studied

- MAC Lung Disease
- Treatment Refractory MAC Lung Disease
- Mycobacterium Infections, Nontuberculous

## Interventions

- **DRUG:** Clofazimine Inhalation Suspension
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06418711
- **Lead sponsor:** Mannkind Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-09-11
- **Primary completion:** 2025-11-10
- **Final completion:** 2025-11-10
- **Target enrollment:** 132 (ACTUAL)
- **Why stopped:** Futility
- **Last updated:** 2025-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06418711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06418711, "ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06418711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*